title: Lentiviral vector design for optimal T cell receptor gene expression in the transduction of peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
abstract: Lentiviral vectors containing promoters of distinct origins, that is, strong viral promoters (cytomegalovirus [CMV] and murine stem cell virus [MSCV]), a cellular promoter (phosphoglycerate kinase [PGK]), and two composite promoters (CAG [a composite promoter sequence comprised of the CMV enhancer and portions of the chicken beta-actin promoter and the rabbit beta-globin gene] and SV40/CD43), were used to evaluate green fluorescent protein (GFP) reporter gene expression in human primary peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes (TILs). In PBLs, vectors containing the MSCV promoter were found to be optimal for expression in both minimally stimulated and highly activated lymphocytes. The stability of gene expression was monitored for up to 7 weeks in culture and the MSCV promoter-containing vector was found to be comparable to the cellular PGK promoter-containing vector. The MSCV promoter-containing lentiviral vector was also the most active in transduced TILs and these cells retained biological activity as measured by antimelanoma antigen reactivity. Using the knowledge gained in comparing individual promoters, a series of two-gene-containing lentiviral vectors was constructed in an attempt to produce the alpha and beta chains of antitumor antigen T cell receptors (TCRs). Dual-promoter or internal ribosome entry site (IRES)-containing vector designs were evaluated and found to be unable to produce both chains of the TCR in amounts that led to significant biological activity. In contrast, if the alpha and beta chains were linked by a 2A ribosomal skip peptide, both proper TCR chain pairing and biologically activity were observed. This paper emphasizes the need to optimize both promoter function and protein synthesis in constructs that require stoichiometric production of multiple protein subunits.
authors.affiliation: Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Stephanie
authors.initials: S
authors.lastname: Jones
authors.forename: Peter D
authors.initials: PD
authors.lastname: Peng
authors.forename: Shicheng
authors.initials: S
authors.lastname: Yang
authors.forename: Cary
authors.initials: C
authors.lastname: Hsu
authors.forename: Cyrille J
authors.initials: CJ
authors.lastname: Cohen
authors.forename: Yangbing
authors.initials: Y
authors.lastname: Zhao
authors.forename: John
authors.initials: J
authors.lastname: Abad
authors.forename: Zhili
authors.initials: Z
authors.lastname: Zheng
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
authors.forename: Richard A
authors.initials: RA
authors.lastname: Morgan
mesh_terms: D000941:Antigens / Q000276:immunology; D002460:Cell Line; D005786:Gene Expression Regulation; D005822:Genetic Vectors / Q000235:genetics*; D049452:Green Fluorescent Proteins / Q000378:metabolism; D006801:Humans; D016086:Lentivirus / Q000235:genetics*; D016131:Lymphocyte Subsets / Q000378:metabolism*; D016246:Lymphocytes, Tumor-Infiltrating / Q000378:metabolism*; D011948:Receptors, Antigen, T-Cell / Q000235:genetics*; D014161:Transduction, Genetic; D019076:Transgenes; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
chemical_list: D000941:Antigens; D011948:Receptors, Antigen, T-Cell; D016159:Tumor Suppressor Protein p53; D049452:Green Fluorescent Proteins